iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
April 08, 2024 16:29 ET
|
iCAD, Inc.
NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its...
iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)
April 03, 2024 08:00 ET
|
iCAD, Inc.; RAD-AID International
NASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global...
iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale
April 02, 2024 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of...
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
March 19, 2024 09:00 ET
|
iCAD, Inc.
NASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
March 12, 2024 16:01 ET
|
iCAD, Inc.
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H.,...
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
February 28, 2024 08:05 ET
|
iCAD, Inc.
Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially...
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)
February 27, 2024 09:05 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably...
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
February 27, 2024 08:05 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 06, 2024 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
January 30, 2024 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...